resmetirom (Rezdiffra)
Jump to navigation
Jump to search
Indications
- treatment of nonalcoholic steatohepatitis (NASH) with fibrosis[1]
Dosage
Adverse effects
Mechanism of action
- liver-directed, thyroid hormone receptor beta agonist
- reduces hepatic fibrosis in patients with NASH
- 14-16% reduction in LDL cholesterol
More general terms
References
- ↑ 1.0 1.1 Bassett M Resmetirom Poised to Become First NASH Treatment. Phase III study demonstrated drug is effective in resolving NASH and improving liver fibrosis. MedPage Today February 7, 2024 https://www.medpagetoday.com/gastroenterology/generalhepatology/108629
FDA News Release U.S. Food and Drug Administration.FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA 2024 Mar 14; https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
Harrison SA, Bedossa P, Guy CD et al A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024; 390:497-509. Feb 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38324483 https://www.nejm.org/doi/full/10.1056/NEJMoa2309000
Cusi K. Selective agonists of thyroid hormone receptor beta for the treatment of NASH. N Engl J Med 2024 Feb 8; 390:559 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38324491 https://www.nejm.org/doi/10.1056/NEJMe2314365